Thomas Evans

Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.

Mark R. Middleton, Neil Steven, Thomas Evans et al. · Journal of Clinical Oncology · 2016 · 43 citations

Solid Tumor Efficacy, Immunology, Immunoediting +18

Final results from cohort 1 of a phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC)

Thomas Evans, Rajesh Ramanathan, Salim Yazji et al. · Journal of Clinical Oncology · 2007 · 25 citations

Endothelial Cells, Immunology, Cohort 1 +19

Preclinical and Nonclinical Characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for the Treatment of Multiple Myeloma

Che‐Leung Law, Wade H. Aaron, Rick Austin et al. · Blood · 2018 · 19 citations

HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors

Mary E. Molloy, Wade H. Aaron, Manasi Barath et al. · Molecular Cancer Therapeutics · 2024 · 17 citations · Full text

Abstract C033: HPN328: An anti-DLL3 T cell engager for treatment of small cell lung cancer

Wade H. Aaron, Richard J. Austin, Manasi Barath et al. · Molecular Cancer Therapeutics · 2019 · 13 citations

Immunology, Immunoediting, Immunotherapeutics +17